Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
4DMT Presents Positive Interim Data from Randomized Phase II PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD 4D Molecular Therapeutics, a prominent company in the field of genetic medicines with a focus on harnessing the full potential of geneti...
Find More
Axovant rely on new gene therapy, Rise in Shares Roivant Neuro Company has licensed Oxford Biomedica’s gene therapy OXB-102, now AXO-Lenti-PD, for Parkinson’s disease (PD). Spark Therapeutics’ Former CTO Fraser Wright, Ph.D has been hired as its new CTO. Axovant expects to stimulate a phase 1/2 dose escalation stu...
Find More
Arbor Biotechnologies shining with new CRISPR enzyme Arbor Biotechnologies is shining with its new CRISPR enzyme and has successfully bagged USD 15.6 million in series A funding. The company has recently announced its first scientific discovery of a new enzyme, Cas13d, a CRISPR-Cas13 enzyme. It could offer advantag...
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
